MedTrace Logo

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-05

No results posted yet for this study

Summary

We will prospectively observe patients with uveitis who are either active or were recently active in the previous 6 months and are treated with the i-FA implant. All of the patients will have standard clinical exams at baseline and image quantification of their inflammation using OCT, OCTA and UWFFA (if needed). At baseline, ETDRS vision will be measured. Patients will be followed for 12 months months. During follow-up repeat imaging will be performed along with standard examinations, visual acuity and contrast sensitivity measurements. At the final visit, all tests will be repeated. Data collected will be analyzed using statistical software package. Correlations between changes in imaging quantification of inflammation scores and changes in visual acuity, clinical grades of inflammation, and contract sensitivity will be calculated.

Conditions

  • Uveitis

Interventions

DRUG

Fluocinolone Acetonide

Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Sunil K Srivastava, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2026-02-01
Completion
2026-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340505 on ClinicalTrials.gov